Natural Killer cells as COVID-19 therapy (Record no. 75893)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 02025nim a2200481 a 4500 |
001 - CONTROL NUMBER | |
control field | HST8205 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | UkLoHST |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
fixed length control field | m o h |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | cr nna|||||||| |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
fixed length control field | sr |mnnnnnzne| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 201204s2020 enk|||||o||h||||||||eng d |
028 50 - PUBLISHER NUMBER | |
Publisher number | 8205 |
Source | Henry Stewart Talks |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (UkLoHST)4473 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | UkLoHST |
Language of cataloging | eng |
Transcribing agency | UkLoHST |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Kennedy, Pippa, |
Affiliation | (University of Minnesota, USA) |
Relator code | spk |
245 10 - TITLE STATEMENT | |
Title | Natural Killer cells as COVID-19 therapy |
Medium | [electronic resource] / |
Statement of responsibility, etc. | an interview with Pippa Kennedy. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Place of publication, distribution, etc. | London : |
Name of publisher, distributor, etc. | Henry Stewart Talks, |
Date of publication, distribution, etc. | 2020. |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 1 online resource (1 streaming audio file (14 min.)). |
490 1# - SERIES STATEMENT | |
Series statement | Interviews on Covid-19, |
International Standard Serial Number | 2056-452X |
500 ## - GENERAL NOTE | |
General note | Audio interview. |
500 ## - GENERAL NOTE | |
General note | Title from title frames. |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Contents: The role of Natural Killer (NK) cells in viral infections -- Why NK cells are being investigated -- Induced pluripotent stem cell derived natural killer cells for SARS-CoV-2 therapy -- Benefits of this therapy -- Current stage of the clinical trial. |
506 ## - RESTRICTIONS ON ACCESS NOTE | |
Terms governing access | Access restricted to subscribers. |
538 ## - SYSTEM DETAILS NOTE | |
System details note | Mode of access: World Wide Web. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Clinical trials. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | COVID-19 (Disease) |
General subdivision | Treatment. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Killer cells |
General subdivision | Therapeutic use. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Natural immunity. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Clinical Trials, Phase I as Topic. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Coronavirus Infections |
General subdivision | drug therapy. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Coronavirus Infections |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | COVID-19 |
General subdivision | therapy. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Induced Pluripotent Stem Cells. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Killer Cells, Natural |
General subdivision | drug effects. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Killer Cells, Natural |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pneumonia, Viral |
General subdivision | drug therapy. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pneumonia, Viral |
General subdivision | immunology. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | SARS-CoV-2. |
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Virus Diseases |
General subdivision | immunology. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
Uniform title | Henry Stewart talks. |
Name of part/section of a work | Biomedical & life sciences collection. |
-- | Interviews on Covid-19. |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Host name | https://hstalks.com/bs/4473/ |
856 42 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://hstalks.com/bs/p/1060/">https://hstalks.com/bs/p/1060/</a> |
Materials specified | Series |
No items available.